

INSTITUTIONAL BIOSAFETY COMMITTEE MEETING
PROVIDENCE PORTLAND MEDICAL CENTER
Minutes of July 7, 2026
Location: Virtual on Teams

Attendees: (X) if absent

Will Redmond, PhD – Chair	<i>Melissa Kasiewicz (non-voting)</i>		GUESTS: <i>Sasha Stanton, MD</i> <i>Tracy Kelley</i> <i>Stacy Mellinger</i> <i>Nicki Moxon</i>
<i>Matthew Philpott, PhD (x)</i>	<i>Michael Munks, PhD</i>	<i>Andrew Weinberg, PhD</i>	
<i>Tacy Brotherton</i>	<i>Tong Zhang, PhD</i>	<i>Jennifer Wilk, DVM, DACLAM</i>	
<i>Angela Wang (x)</i>			

Call To Order: The Institutional Biosafety Committee (IBC) Administrator called the meeting to order at 1:06pm . A quorum was present.

TOPIC	DISCUSSION / RESULTS	ACTION
New Protocol Review: #177 "A Phase 1, Multicenter, Open-label, First-in-Human Study of ITI-5000 (Self-Amplifying RNA Vaccine) Alone and in Combination with Pembrolizumab in Participants with Stage II–III Triple-Negative Breast Cancer (TNBC) Who Have Completed Standard Curative-Intent Therapy (VITAL-TNBC Study)	The study’s primary objective is to evaluate the safety and efficacy of ITI-5000, a Self-Amplifying RNA Vaccine targeting HERV-K, CT83 and LAMP-1, in an adjuvant setting, in participants with Triple-Negative Breast Cancer. Committee discussed the study and had the following comments: 1) I.1 Please reference NIH Guideline III-C-1. 2) II.8 Please note annual Sharps training of medical personnel.	Motion to approve with administrative edits; seconded.

Approve Minutes from May 14, 2026 Ad hoc Meeting	Committee reviewed minutes from May 14, 2026.	Motion to approve; seconded.
---	---	---------------------------------

Meeting adjourned at approximately 1:13 pm.